Vetr Crowd Bearish On GW Pharma, But Upgrades To 3-Star Rating
GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.
The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.
Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.
At time of writing, GW Pharma was up 1.64 percent at $93.07.
Latest Ratings for GWPH
|Oct 2016||Leerink Swann||Assumes||Outperform|
|Sep 2016||Morgan Stanley||Maintains||Overweight|
|Sep 2016||Cantor Fitzgerald||Maintains||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.